This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The need for better treatments for Alzheimer disease (AD) is more urgent than ever.1 In the last couple of decades, AD researchers have examined the potential value of existing drugs as treatments for AD. Among these are statins, which were first discovered in the 1970s. These drugs, primarily indicated for the treatment of hypercholesterolemia and prevention of cardiovascular disease, are among the most widely prescribed drugs in the United States today. According to a recent report by the National Center for Health Statistics, antihyperlipidemic drugs, including statins, are the second most commonly mentioned group of drugs during medical office visits, and atorvastatin specifically was the second most commonly mentioned individual drug overall (after aspirin).2 Prior data have suggested that hypercholesterolemia may contribute to AD and that statins may provide a potential benefit; other statin mechanisms of action may also be important. The result has been a large body of observational work on statins and AD. Preclinical studies have shown promise, yet results from clinical observational studies and the little data available from small clinical trials3 have yielded mixed findings.
In this issue of Neurology®, Feldman et al.4 evaluate the efficacy and safety of atorvastatin in …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen